ORIC-944 for metastatic prostate cancer after hormone therapy
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This early-phase trial tests ORIC-944 to see how well it works and what dose is safest for metastatic prostate cancer that has progressed after hormone-targeted pills. It may help people whose cancer has stopped responding to prior prostate cancer hormone treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have metastatic prostate cancer that has spread beyond the prostate
- You’ve had both testicles removed, or you will continue a hormone shot/pill (GnRH) to keep testosterone at very low “castrate” levels
- Your prior prostate cancer treatments fit one of the trial’s specific plans (the trial checks which hormone pills and how many chemo treatments you’ve had)
- Cancer is clearly getting worse based on specific PSA, scan, or bone/soft-tissue progression rules
- You can have skin and core tumor biopsies during the study
- Your day-to-day function is good (ECOG 0–1) and your organs (blood, kidney, liver) meet safety lab requirements
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, talazoparib and enzalutamide, in men with advanced prostate cancer that has progressed after previous treatment with a hormone therapy called an AR inhibitor. It aims to see if this combination can help control the cancer and delay further progression.
This study tests several new drug combinations for men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. It aims to find better ways to control the disease and improve outcomes.
This study tests an experimental pill called rinzimetostat (ORIC-944) for men with advanced prostate cancer that has spread and stopped responding to abiraterone. It may offer a new option if you have not had many other treatments yet.
This study tests a new targeted therapy called inavolisib for men with advanced, hormone-resistant prostate cancer that has spread. The drug may work by blocking a specific pathway that helps cancer grow. Participants must have already tried one second-generation hormone therapy and have a tumor sample available for testing.
This trial is testing a new combination therapy for men with advanced prostate cancer that has stopped responding to hormone treatment. The goal is to see if this treatment can shrink tumors or slow down the cancer, and it may offer a new option when standard treatments have not worked.
This study tests different ways of giving hormone therapy to find the right dose for men with prostate cancer that has spread. It aims to help manage the disease while limiting side effects.
Hear when a new Metastatic Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.